Biomerica, Inc. (BMRA) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Biomerica, Inc. (BMRA) closed at USD 1.88 on 2026-10-15, a change of -32.6 % over the past year, with a market capitalization of USD 8.51M.

Biomerica, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Biomerica, Inc. key figures

Previous close

USD 1.88 (2026-10-15)

1-year change

-32.6 %

Market cap

USD 8.51M

Enterprise value

USD 9.68M

P/E ratio (trailing)

-1.42

P/E ratio (forward)

4.74

EPS (trailing)

-1.30

EPS (forward)

0.39

PEG ratio

n/a

Price to book

2.25

Revenue growth

16.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.75

Employees

50

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Biomerica, Inc.

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Biomerica, Inc. and compare it with other stocks.